2022年1月6日 · 有研究显示肺癌中肿瘤的细胞形态、ki-67阳性率和pcna，以及临床分期和组织学分化为预测肺癌的发展和预后提供了有用信息。单变量和多变量生存分析显示，pbk/topk表达与nsclc的不良预后显著相关。

In 2009, the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group formed to address the problem of inter-laboratory inconsistency in Ki67 assessment.

2023年5月24日 · Ki-67是一种细胞增殖标志物，可以检测细胞周期中的细胞比例。 Ki-67的阳性率越高，说明肿瘤细胞处于生长周期的比例越大，肿瘤的生长速度越快。 例如，某患者的Ki-67检测结果是30%阳性。

Additionally, randomised studies have retrospectively reviewed data and reported on the role of Ki67 in breast cancer. In light of new data, we have re-assessed evidence that could change guidelines to include Ki67 in the standard pathological assessment of early breast cancers.

Ki-67 protein has been widely used as a proliferation marker for human tumor cells for decades. In recent studies, multiple molecular functions of this large protein have become better understood. Ki-67 has roles in both interphase and mitotic cells, and its cellular distribution dramatically changes during cell cycle progression.

6 天之前 · Internal test set validation in clinical application indicated significantly lower disease-free survival in the high Ki-67 expression group compared to the low expression group (P = 0.005).

NRCM were treated with XMU-MP-1 (1-3 μM) for 24 hr prior to fixation and immunostaining. (b) Analysis of Ki-67 positive cells indicated that treatment with XMU-MP-1 at a dose of 3 μM...

2020年12月28日 · MKI67 encodes for Ki-67, a nuclear protein that constitutes an integral component of the mitotic chromosome periphery, preventing chromosomes from collapsing into a single chromatin mass after nuclear envelope disassembly. This protein has been shown to be essential for independent chromosome motility and interactions with the mitotic spindle (6).

2021年7月1日 · Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in breast cancer, has limited value for treatment decisions due to questionable analytical validity.

2024年5月22日 · Cell proliferation, as measured by Ki67, is considered a significant predictive factor for the success of neoadjuvant chemotherapy (NACT) in breast cancer. However, its clinical utility remains debated. This study aimed to determine the optimal cut-off value for Ki67 and evaluate its predictive potential in this context.